Skip to main content
SCYNEXIS INC logo

SCYNEXIS INC — Investor Relations & Filings

Ticker · SCYX ISIN · US8112922005 LEI · 529900XBHFGMNTU70154 US Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2016-11-07 Interim / Quarterly Rep…
Country US United States of America
Listing US SCYX

About SCYNEXIS INC

https://www.scynexis.com/

SCYNEXIS, Inc. is a biotechnology company focused on the discovery and development of novel anti-infectives to overcome difficult-to-treat and drug-resistant fungal infections. The company is pioneering a new class of broad-spectrum antifungal agents called 'fungerps,' which are triterpenoid-based compounds. These agents are being developed in both oral and intravenous formulations to treat a range of serious, invasive, and life-threatening fungal diseases, particularly those encountered in hospital environments. SCYNEXIS aims to address the significant global health threat of antifungal resistance by providing innovative therapeutic options where existing treatments are limited or ineffective. The company's development pipeline includes second-generation fungerp candidates.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2016
2016-11-07 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 30, 2016, reporting a material definitive agreement (a Loan and Security Agreement) and related financial obligations. It details the terms of a secured term loan, interest rates, covenants, and issuance of warrants. The document also includes information about unregistered sales of equity securities related to the loan. The content focuses on financing activities and capital structure changes, specifically the creation of a direct financial obligation and issuance of warrants. There are no financial statements or quarterly/annual financial results presented, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a regulatory certification or a voting result announcement. The primary subject is a financing update regarding a loan agreement and related warrants. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (7436 characters) supports it being a substantive filing rather than a brief announcement or report publication notice.
2016-10-05 English
FORM 4
Director's Dealing
2016-10-04 English
FORM 4
Director's Dealing
2016-10-04 English
FORM 4
Director's Dealing
2016-09-16 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-08-10 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.